Nutritional and Lifestyle Therapy for NAFLD in People with HIV
- PMID: 37111209
- PMCID: PMC10140991
- DOI: 10.3390/nu15081990
Nutritional and Lifestyle Therapy for NAFLD in People with HIV
Abstract
HIV infection and nonalcoholic fatty liver disease (NAFLD) are two major epidemics affecting millions of people worldwide. As people with HIV (PWH) age, there is an increased prevalence of metabolic comorbidities, along with unique HIV factors, such as HIV chronic inflammation and life-long exposure to antiretroviral therapy, which leads to a high prevalence of NAFLD. An unhealthy lifestyle, with a high dietary intake of refined carbohydrates, saturated fatty acids, fructose added beverages, and processed red meat, as well as physical inactivity, are known to trigger and promote the progression of NAFLD to nonalcoholic steatohepatitis, liver fibrosis, and hepatocellular carcinoma. Furthermore, with no currently approved pharmacotherapy and a lack of clinical trials that are inclusive of HIV, nutritional and lifestyle approaches still represent the most recommended treatments for PWH with NAFLD. While sharing common features with the general population, NAFLD in PWH displays its own peculiarities that may also reflect different impacts of nutrition and exercise on its onset and treatment. Therefore, in this narrative review, we aimed to explore the role of nutrients in the development of NAFLD in PWH. In addition, we discussed the nutritional and lifestyle approaches to managing NAFLD in the setting of HIV, with insights into the role of gut microbiota and lean NAFLD.
Keywords: HIV; MAFLD; NAFLD therapy; diet; exercise; fatty liver; food insecurity; lean NASH; lifestyle; microbiota; nutrients.
Conflict of interest statement
G.S. acted as speaker for Merck, Gilead, Abbvie, Novonordisk, Pfizer, served as an advisory board member for Pfizer, Merck, Novonordisk, Gilead, and has received unrestricted research funding from Theratechnologies Inc. G.G. received a research grant and speaker honoraria from Gilead, ViiV, Merck and Jansen and attended advisory boards of Gilead, ViiV and Merck. F.C., A.C. and R.L. declare no conflict of interest.
Figures
References
-
- Global HIV & AIDS Statistics—Fact Sheet. [(accessed on 28 January 2023)]. Available online: https://www.unaids.org/en/resources/fact-sheet.
-
- Croxford S., Kitching A., Desai S., Kall M., Edelstein M., Skingsley A., Burns F., Copas A., Brown A.E., Sullivan A.K., et al. Mortality and Causes of Death in People Diagnosed with HIV in the Era of Highly Active Antiretroviral Therapy Compared with the General Population: An Analysis of a National Observational Cohort. Lancet Public Health. 2017;2:e35–e46. doi: 10.1016/S2468-2667(16)30020-2. - DOI - PubMed
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical
Research Materials
